A5038918684- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Molecular Biology Techniques and Applications
- Lung Cancer Treatments and Mutations
- Bone health and treatments
- Freshwater macroinvertebrate diversity and ecology
- Aquatic Invertebrate Ecology and Behavior
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Metabolism, Diabetes, and Cancer
- Fish Ecology and Management Studies
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Soil and Water Nutrient Dynamics
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Medical Imaging Techniques and Applications
- Bone Metabolism and Diseases
- Species Distribution and Climate Change
- Aquatic Ecosystems and Phytoplankton Dynamics
- Prostate Cancer Treatment and Research
- Metastasis and carcinoma case studies
Austrian Breast & Colorectal Cancer Study Group
2016-2025
Statistics Austria
2013-2025
University of Salzburg
2023
Medical University of Vienna
2011-2021
Ludwig Boltzmann Institute for Cancer Research
2021
Medical University of Graz
2011-2019
Comprehensive Cancer Center Vienna
2011-2019
Paracelsus Medical University
2011-2019
Nanostring Technologies (United States)
2013-2019
German Breast group
2019
We have previously shown that the PAM50-based risk of recurrence (ROR) score is significantly correlated with distant in both translational research cohort within Arimidex, Tamoxifen Alone or Combination (ATAC) trial (TransATAC) and Austrian Breast Colorectal Cancer Study Group 8 (ABCSG 8) randomized trials. Here, we focus on ROR for predicting after 5 years follow-up a combined analysis these two
Abstract Purpose: To assess the prognostic value of PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort postmenopausal, endocrine-responsive breast cancer patients. Experimental Design: The assay was performed formalin-fixed paraffin-embedded whole-tumor sections patients who had been enrolled Austrian Breast Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels genes were determined centrally using...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
For postmenopausal women with hormone-receptor-positive breast cancer, the most effective duration for adjuvant therapy an aromatase inhibitor remains unclear.In this prospective, phase 3 trial, we randomly assigned cancer who had received 5 years of endocrine to receive anastrozole additional 2 (2-year group, receiving a total 7 years) or (5-year 10 years). The primary end point was disease-free survival. analysis included all patients were still participating in trial and no recurrence...
Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor-positive breast cancer. According to the hypothesis that overweight have higher levels of aromatase enzyme availability, we investigated influence body mass index (BMI) on efficacy adjuvant therapy in premenopausal a retrospective analysis Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 trial.ABCSG-12 examined ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days)...
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
Summary 1. Studies on biodiversity and ecosystem function require considering metrics for accurately describing the functional diversity of communities. The number taxa (richness) is commonly used to characterise biological diversity. disadvantage richness as a measure that all are taken into account an equal basis regardless their abundance, characteristics or in ecosystem. 2. To circumvent this problem, we applied recently described incorporates dissimilarities among taxa. Dissimilarities...
Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, minimally invasive of tumor based on cell-free circulating DNA (ctDNA) may be beneficial to guide decisions.
PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation PALLAS. METHODS Patients with stage II-III HR+, HER2– disease were randomly assigned 2 years ET versus alone. primary...
We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment. The ABCSG-6a trial re-randomised event-free postmenopausal hormone receptor-positive the ABCSG-6 to receive either 3 additional years of endocrine therapy using anastrozole vs nil. In this retrospective analysis, we prognostic and impact BMI on disease outcome safety. all, 634 (177 normal weight, 307 overweight, 150 obese) were...
Neoadjuvant chemotherapy (NaCT) and neoadjuvant endocrine therapy (NET) can reduce pre-operative tumour burden in patients with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative early-stage breast cancer. This prospective translational study assessed the ability of a 12-gene molecular score (MS; EndoPredict®) to predict response NaCT or NET within ABCSG-34 trial.Hormone (HR)-positive, HER2-negative samples from randomized phase II trial were selected...
BACKGROUND: Adjuvant aromatase inhibitors increase osteoporosis and fractures in patients with hormone receptor–positive breast cancer. We have previously reported outcomes of the ABCSG-18 (study 18 from Austrian Breast & Colorectal Cancer Study Group) trial showing that adjuvant anti–receptor activator nuclear factor-κB ligand denosumab treatment counteracts these adverse effects may improve outcomes. report here final long-term METHODS: is a prospective, double-blind, placebo-controlled,...
Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy anticancer agents. In the phase III PALLAS trial, addition palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use PPIs affected outcomes treated PALLAS.